UPDATE -- Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company's Strategy, Vision and Execution
WALTHAM, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. ("Eloxx") (OTCQB:SVOND), a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat rare and ultra-rare genetic diseases caused by nonsense mutations today announced that Robert ("Bob") Ward has been appointed Chairman of the Board of Directors of Eloxx (the "Board") and Chief Executive Officer effective immediately. Bob succeeds outgoing Chairman of the Board, Robert Heft, and current founder and Chief Executive Officer Dr. Silvia Noiman at a critical inflection point for Eloxx as the company advances its lead candidate ELX-02, a novel translational read-through inducing drug (TRID), through the completion of Phase 1 clinical trials and navigates its transition from a private to a public company.
Mr. Ward brings to Eloxx more than 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development, commercialization, and strategic business development transactions. Mr. Ward most recently was the President and Chief Executive Officer of Radius Health, Inc. ("Radius").
"We are pleased to have attracted an experienced leader with Bob's proven track record of success to Eloxx," said Dr. Robert Heft. "Having previously lead a fully integrated commercial biopharmaceutical company to achieve its first drug approval and product launch, we are confident that Bob is the right leader to advance Eloxx as we seek to develop and commercialize our novel small molecule medicines to treat rare and ultra-rare genetic diseases."
"Bob has already built substantial value for patients, employees, and shareholders through his management of the development and commercialization of important drugs, transformative business development transactions and substantial financings," said Dr. Noiman. "As a fellow Board member, I look forward to working with Bob during the transition as we advance our pipeline and build Eloxx."
"I am excited to have the opportunity to lead Eloxx and build upon the successful work of Drs. Heft and Noiman. Today the Company is poised to accelerate our portfolio and to potentially improve the lives of patients with rare diseases while continuing to build our Company and create substantial value for shareholders and our employees," said Mr. Ward. "We are grateful for Dr. Heft's service and many contributions to the Board and our shareholders."
Mr. Ward was formerly the President and Chief Executive Officer of Radius, where he helped the company successfully complete its Initial Public Offering in 2014, and lead the development, approval and launch of the company's TYMLOS(TM) injection. He is a global pharmaceutical industry leader managing all stages of drug development, commercialization, and strategic deal making and partnerships across multiple therapeutic areas. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca from 2011 to 2013. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016. He served as a Director of Radius from December 2013 until July 16, 2017. Mr. Ward serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. Nonsense mutations are a class of genetic defects that result in premature termination of protein synthesis. These nonsense mutations have been identified in over 2,000 rare and ultra-rare diseases. As a consequence, patients with a genetic disease caused by nonsense mutations have absent or truncated nonfunctional proteins, accounting for some of the most severe phenotypes in these genetic diseases. Eloxx's lead product candidate, ELX-02, is an investigational, novel translational read-through inducing drug designed to restore synthesis of full-length functional proteins. ELX-02 is an investigational agent undergoing clinical trials and has not been approved by any global regulatory body. Eloxx was founded in 2013 and is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company's ability to continue as a going concern; the ability of the Company to consummate additional financings; the development of the Company's antibody technology; the approval of the Company's patent applications; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products; the timing and success of the Company's preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company's common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update or revise such forward-looking statements to reflect subsequent events or circumstances.
Greg Weaver, CFO
Barbara Ryan Advisors
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eloxx Pharmaceuticals via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Canada's CoinField cryptocurrency exchange going international with commission-free trading app moonGO through a new partnership23.7.2018 11:30 | Pressmeddelande
moonGO(TM) app is the fastest and most reliable way to buy/sell and store cryptocurrencies. The app allows users to convert cryptos directly to EUR/USD to be loaded into their moonGo(TM) card and be used anywhere worldwide whether they're shopping online or spending it at a physical retailer who accepts credit cards. VANCOUVER, British Columbia, July 23, 2018 (GLOBE NEWSWIRE) -- CoinField, the most advanced cryptocurrency exchange in Canada is now extending its services worldwide thanks to a new partnership with Malta's Manticore Ventures to create moonGO(TM), a powerful app designed for traders who thrive on agility, flexibility and security. With moonGO(TM), users can set up their trading accounts in about 60 seconds, withdraw fiat currency as Euro or US dollars in the form of moonGO(TM) cards, and use the moonGO(TM) cards to make purchases online or at any retailer that accepts credit cards. The moonGO(TM) app will take CoinField's sterling reputation outside of Canada and make its
UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance23.7.2018 09:00 | Pressmeddelande
BASHH aiming to raise awareness of Mgen and curb rising antibiotic resistance LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- The British Association of Sexual Health and HIV (BASHH) draft guidelines for the sexually transmitted infection Mycoplasma genitalium (Mgen) were posted for consultation on July 8th, 20181[link]. The guideline recommends Resistance Guided Therapy as best practice when treating an Mgen infection, with a strong recommendation for diagnostic tests to direct appropriate antibiotic treatment. Mgen is highly resistant to antibiotics, up to 50% of infections are already resistant to the first-line treatment, azithromycin.2,3 This rate may rise if infections are treated without knowledge of resistance status. The success of Resistance Guided Therapy as treatment for Mgen was published in Clinical Infectious Diseases, June 20182 [link].Cure rates increased from under 68% to over 92% by switching the first-line drug and using the SpeeDx Resistance Plus® MG* test to triage pati
LeoVegas AB: Inbjudan till presentation av LeoVegas delårsrapport för andra kvartalet 201823.7.2018 08:00 | Pressmeddelande
LeoVegas delårsrapport för det andra kvartalet för 2018 kommer att publiceras klockan 08:00 den 1:a augusti 2018. En webbsänd telefonkonferens kommer att hållas klockan 09:00 samma dag där Gustaf Hagman, VD och medgrundare samt Viktor Fritzén, CFO, presenterar resultatet. Det kommer att finnas möjlighet att ställa frågor via webbsändningen där även presentationsmaterialet går att följa. Webbsändningen nås på adressen: https://edge.media-server.com/m6/p/zupwii5n För att delta i telefonkonferensen via telefon, vänligen ring in på något av följande nummer: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Bekräftelse kod: 5362090 Webbsändningen, som även kan ses i efterhand, och presentationsmaterialet kommer att finnas tillgängligt på LeoVegas webbplats www.leovegasgroup.com under Investor Relations. För ytterligare information, vänligen kontakta: Gustaf Hagman, Group CEO och medgrundare: +46 (0) 8 410 367 66, email@example.com Philip Doftvik, Head of Investor
LeoVegas AB: Invitation to presentation of LeoVegas second quarter 201823.7.2018 08:00 | Pressmeddelande
LeoVegas interim report for the second quarter for 2018 will be published at 08:00 CET on August 1, 2018. A webcast telephone conference will be held at 09:00 CET the same day, where Gustaf Hagman, CEO and Co-founder, and Viktor Fritzén, CFO, will present the results. A possibility will be given to ask questions via the webcast and follow the presentation live. The webcast will be accessible at: https://edge.media-server.com/m6/p/zupwii5n To participate in the conference call by phone, please call one of the following numbers: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Confirmation code: 5362090 The webcast, which afterwards also will be available on demand, and presentation material will be published on LeoVegas website, www.leovegasgroup.com under Investor Relations. For further information, please contact: Gustaf Hagman, Group CEO: +46 (0) 8 410 367 66, firstname.lastname@example.org Philip Doftvik, Head of Investor Relations and corporate finance: +46 73 512 0
Gratomic Announces Non-Brokered Private Placement21.7.2018 19:41 | Pressmeddelande
TORONTO, July 21, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A143MR) is pleased to announce the offering of a non-brokered private placement of up to 20,000,000 working capital units (the "WC Unit") for up to $2,000,000 (the "Offering"). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant ("WC Warrant"). Each WC Warrant entitles the holder to purchase one (1) common share (a "WC Warrant Share") at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the "Final Trading Day") is at least four (4) months from the Closing Date, the date which is thirty (30) days from the Final Trading Day. Eligible Finders may receive 5% of the value of
eGain Enables Conversational Customer Service Through Apple Business Chat20.7.2018 12:30 | Pressmeddelande
SUNNYVALE, Calif. and NEWBURY, United Kingdom, July 20, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced its integration with Apple Business Chat. According to Gartner, requests for customer support through consumer mobile messaging apps will exceed requests for customer support through traditional social media by 2019*. Moreover, 56% of consumers surveyed in a Nielsen study would rather message a business than call customer service, and 67% expect to message businesses even more over the next two years. Key capabilities Among key capabilities of the integrated solution are: Enabling hundreds of millions of consumers on iPhone and iPad to interact with businesses through the Messages app Leverage eGain AI to infer customer intent, power bot conversations through messaging, route escalations to contact center agents, and guide agents through messaging conversations Provide immersive customer experiences with
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum